Archives
Anti-ROR1 Antibody (Zilovertamab): Mechanism, Evidence & Use
Anti-ROR1 Antibody (Zilovertamab): Mechanism, Evidence & Use
Executive Summary: Anti-ROR1 Antibody (Zilovertamab) is a humanized monoclonal antibody that targets ROR1, a receptor associated with tumorigenesis (source: product_spec). It specifically blocks Wnt5a-induced ROR1 signaling, contributing to anti-tumor effects in preclinical studies (source: workflow_recommendation). The antibody is purified from CHO cells by Protein A chromatography, achieving >95% purity as confirmed by SDS-PAGE and SEC-HPLC (source: product_spec). Zilovertamab is validated for ELISA, FACS, kinetic, and animal model applications (source: workflow_recommendation). Proper storage at -80°C is recommended to preserve stability and biological activity (source: product_spec).
Biological Rationale
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal antigen expressed in various malignancies but absent in most adult tissues, making it an attractive therapeutic target (source: workflow_recommendation). ROR1 signaling, particularly via Wnt5a, supports tumor cell survival, migration, and chemotherapy resistance. Inhibiting ROR1 disrupts these pro-tumorigenic processes. Anti-ROR1 Antibody (Zilovertamab) is designed to selectively bind human ROR1 with high affinity, leveraging its IgG1 isotype for suitable effector functions in preclinical models. Unlike generic antibodies, Zilovertamab’s specificity minimizes off-target interactions, enabling precise mechanistic studies in cancer research (source: workflow_recommendation).
Mechanism of Action of Anti-ROR1 Antibody (Zilovertamab)
Zilovertamab acts by binding to the extracellular domain of ROR1, thereby blocking Wnt5a-induced signal transduction (source: product_spec). By interfering with this pathway, the antibody suppresses downstream effects such as β-catenin activation, cell proliferation, and migration. This targeted inhibition results in reduced tumor growth and enhanced susceptibility to cytotoxic agents in preclinical models. The antibody is unconjugated, allowing for flexible downstream labeling in kinetic assays and functional studies. Its high specificity is confirmed by binding immobilized human ROR1 His-tagged protein at 2 µg/mL (source: product_spec).
Evidence & Benchmarks
- Anti-ROR1 Antibody (Zilovertamab) demonstrates >95% purity by SDS-PAGE and SEC-HPLC (source: product_spec).
- Validated binding to immobilized human ROR1 His-tagged protein at 2 µg/mL confirms specificity (source: product_spec).
- Suitable for ELISA, FACS, kinetic studies, and animal models, supporting broad experimental utility (source: workflow_recommendation).
- Recommended storage at -80°C preserves antibody stability and biological activity; freeze-thaw cycles should be avoided (source: product_spec).
- Produced in CHO cells and purified via Protein A chromatography, ensuring batch-to-batch consistency (source: product_spec).
- Mechanistic studies in cancer models reveal that Wnt5a-induced ROR1 signaling can be selectively inhibited by Zilovertamab, reducing tumor cell proliferation (source: workflow_recommendation).
For an in-depth protocol- and mechanism-focused analysis, see "Anti-ROR1 Antibody (Zilovertamab): Translational Insights and Assay Precision", which this article extends by providing explicit purity, formulation, and workflow integration details. For a complementary technical use guide, refer to "Anti-ROR1 Antibody (Zilovertamab): Technical Use Guide", which covers context-specific application scenarios. These resources complement the present article's emphasis on evidence-backed mechanistic and practical considerations.
Applications, Limits & Misconceptions
Anti-ROR1 Antibody (Zilovertamab) is applicable in multiple experimental formats:
- ELISA: As a capture or detection antibody for quantifying ROR1 expression.
- FACS: For selective labeling and quantification of ROR1-positive cells.
- Kinetic studies: For real-time analysis of ROR1-antibody interactions.
- Functional assays: To evaluate the biological consequences of ROR1 inhibition.
- Animal models: To assess anti-tumor efficacy and target engagement.
However, its utility is limited to systems expressing human ROR1. It is not suitable for species without cross-reactive ROR1 or in samples where preservative-free, IgG1 isotypes are incompatible (source: workflow_recommendation).
Common Pitfalls or Misconceptions
- Misuse in Non-ROR1 Contexts: Zilovertamab is ineffective in models lacking ROR1 expression.
- Improper Storage: Failure to store at -80°C or repeated freeze-thawing reduces activity and stability.
- Buffer Compatibility: The antibody is preservative-free and may require supplementation for long-term storage in some workflows.
- Species Cross-Reactivity: This antibody does not cross-react with rodent ROR1 unless humanized models are used.
- Vortexing During Reconstitution: Aggressive mixing can denature the protein; gentle resuspension is required.
Workflow Integration & Parameters
Protocol Parameters
- ELISA | 2 µg/mL | Human ROR1-expressing cells | Validated for immobilized antigen binding; ensures specificity | product_spec
- FACS | 2–5 µg/mL | Human tumor cell sorting | Concentration range supports optimal labeling | workflow_recommendation
- Kinetic studies | 0.5–5 µg/mL | SPR/BLI platforms | Enables affinity and binding kinetics measurement | workflow_recommendation
- Functional assays | 1–10 µg/mL | In vitro tumor models | Dose titration recommended for cell viability/apoptosis readouts | workflow_recommendation
- Storage | -80°C | All applications | Maintains biological activity and prevents aggregation | product_spec
- Reconstitution | Add sterile distilled water, gentle mixing | All | Prevents protein denaturation; do not vortex | product_spec
Conclusion & Outlook
Anti-ROR1 Antibody (Zilovertamab) from APExBIO represents a rigorously validated tool for targeted inhibition of Wnt5a-induced ROR1 signaling, supporting diverse experimental applications in cancer research. Its defined biophysical properties, high purity, and workflow adaptability make it suitable for mechanistic and translational studies. Ongoing research continues to elucidate the therapeutic promise of ROR1 inhibition (source: product_spec). For related mechanistic insights on cellular injury and signaling disruption relevant to experimental modeling, see "Deoxynivalenol-Induced Liver Injury: Mitophagy and Nrf2 Pathways" (this article clarifies anti-tumor pathway targeting versus general hepatotoxicity), and "Deoxynivalenol Hepatotoxicity: Mitophagy and Nrf2 Pathway Disruption" (offering a mechanistic distinction in non-oncologic settings).
For detailed technical specifications and ordering information, visit the Anti-ROR1 Antibody (Zilovertamab) product page.